Brief: Adocia Says M1pram Phase 2 Trial Meets Primary Objective By Reducing Weight In Overweight People With Type 1 Diabetes

Adocia SA

21/06/2022 17:05

June 21 (Reuters) - Adocia SA  ADOC.PA :
    * ANNOUNCES M1PRAM PHASE 2 TRIAL MEETS PRIMARY OBJECTIVE BY
REDUCING WEIGHT IN OVERWEIGHT PEOPLE WITH TYPE 1 DIABETES
    * DEMONSTRATED WEIGHT LOSS VERSUS. HUMALOG® (-2.13KG) OVER 4
MONTHS WITH PROGRESSIVE AND CONTINUOUS WEIGHT LOSS STILL ONGOING
AT END OF STUDY PERIOD.
    * BOTH TREATMENTS WERE WELL TOLERATED AND OVERALL GOOD
GLYCEMIC
CONTROL IS MAINTAINED IN BOTH GROUPS
    * BETTER CONTROL OF APPETITE EXPRESSED IN PATIENT
SATISFACTION
SCORING AFTER 16 WEEKS OF TREATMENT (82.4% WITH M1PRAM VERSUS.
43.2% WITH HUMALOG®)

Source text for Eikon:  ID:nBw36wH2qa 
Further company coverage:  ADOC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))